(ChemotherapyAdvisor) – Image-guided percutaneous core biopsy of renal masses (RMB) allows highly accurate differentiation of benign and malignant renal masses with few complications, according to results from a retrospective study presented at the Radiological Society of North America (RSNA)’s 2012 Scientific Assembly and Annual Meeting in Chicago, IL.

“Percutaneous image-guided RMB is safe and highly diagnostic when combined with IHC studies, and supports a greater role of RMB with imaging to sub-classify renal masses,” reported senior coauthor Steven Raman, MD, of the Ronald Reagan UCLA Medical Center in Los Angeles, CA, and coauthors.

The authors analyzed medical records for 159 patients (71.7% male; mean age, 69 years) who underwent RMB during 2002 to 2012.

Continue Reading

Image-guided RMB had a malignancy-detection sensitivity of 100% and specificity of 100%, the coauthors reported.

Patients experienced relatively low rates of complications, most of which were minor, the authors noted.

“There were a total of 12 (7.4%) complications, 11 minor (6.8%) and 1 major,” they reported. “Of the minor complications, 7 (4.3%) were post-procedural minor hematomas that resolved conservatively; 1 (0.6%) post-procedural vasovagal reaction; 1 (0.6%) cases of hematuria; and 2 (1.2%) cases of small free fluid in the pelvis.”

The technique will allow “more targeted management of renal masses,” the coauthors concluded.